Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)
DiNardo CD., Dohner H., Zeidan AM., Schuh AC., Vyas P., Stein EM., Wei AH., de Botton S., Chen C., Lord-Bessen J., Martin-Regueira P., Lersch F., Gong J., Guo S., Shi L., Montesinos P.